Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome

Haematologica

Volumn 91, Issue 11, 2006, Pages 1473-1480

  Langebrake, Claudia ^a   Klusmann, Jan Henning ^a   Wortmann, Kristina ^b   Kolar, Miriam ^b   Puhlmann, Ulrike ^a   Reinhardt, Dirk ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Down's syndrome; Leukemogenesis; NCAM; RUNX1

Indexed keywords

CD56 ANTIGEN; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR RUNX1;

ARTICLE; BONE MARROW; CONTROLLED STUDY; DOWN SYNDROME; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MYELOID LEUKEMIA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

ADOLESCENT; BONE MARROW CELLS; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DOWN SYNDROME; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HUMANS; INFANT; LEUKEMIA, MYELOID; MALE; NEURAL CELL ADHESION MOLECULES;

EID: 33750950626     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001;2:429-36.
2. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003;17:277-82.
3. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down's syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 2005;217:126-34.
4. Karandikar NJ, Aquino DB, Mckenna RW, Kroft SH. Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. An immunophenotypic analysis. Am J Clin Pathol 2001;116:204-10.
5. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci USA 2006;103:3339-44.
6. Lightfoot J, Hitzler JK, Zipursky A, Albert M, Macgregor PF. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia 2004;18:1617-23.
7. McElwaine S, Mulligan C, Groet J, Spinelli M, Rinaldi A, Denyer G, et al. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing FRAME as a specific discriminating marker. Br J Haematol 2004;125:729-42.
8. Diekamp S, Creutzig U, Reinhardt D, Baumann-Köhler M. Transitorisch myeloproliferatives Syndrom bei Neugeborenen mit Down-Syndrom. Überblick und Analyse von 115 Patienten aus den AML-BFM-Studien und der ESPED-Studie. Monatsschrift Kinderheilkunde 2004;154:162-8.
9. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, van Zantwijk CH, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 2002;99:245-51.
10. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005;19:1355-60.
11. Groet J, McElwaine S, Spinelli M, Rinaldi A, Burtscher I, Mulligan C, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 2003;361:1617-20.
12. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003;101:4301-4.
13. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003;101:4298-300.
14. Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003;102:981-6.
15. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148-52.
16. Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, et al. Natural history of GATA1 mutations in Down syndrome. Blood 2004;103:2480-9.
17. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leuemia. Haematologica 2002;87:250-6.
18. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994;8:823-6.
19. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001;15:1161-4.
20. Mann KP, DeCastro CM, Liu J, Moore JO, Bigner SH, Traweek ST. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. Am J Clin Pathol 1997;107:653-60.
21. Wang X, Hisha H, Taketani S Inaba M, Li Q, Cui W, et al. Neural cell adhesion molecule contributes to hemopoiesis-supporting capacity of stromal cell lines. Stem Cells 2005;23:1389-99.
22. Zhang YW, Bae SC, Huang G, Fu YX, Lu J, Ahn MY, et al. A novel transcript encoding an N-terminally truncated AML1/PEBP2 αB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol Cell Biol 1997;17:4133-45
23. Taketani T, Taki T, Takita J, Ono R, Horikoshi Y, Kaneko Y, et al. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia 2002;16:1866-7.
24. Taketani T, Taki T, Takita J, Tsuchida M, Hanada R, Hongo T, et al. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies. Genes Chromosomes Cancer 2003;38:1-7.
25. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996;84:321-30.
26. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004;10:299-304.
27. Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004;103:399-406.
28. Osato M, Ito Y. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia? Crit Rev Eukaryot Gene Expr 2005;15:217-28.
29. Xu G, Kanezaki R, Toki T, Watanabe S, Takahashi Y, Terui K, et al. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome. Leukemia 2006;20:1002-8.
30. Bjerregaard MD, Jurlander J, Klausen P, Borregaard N, Cowland JB. The in vivo profile of transcription factors during neutrophil differentiation in human bone marrow. Blood 2003;101:4322-32.
31. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
32. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-5.
33. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460-2.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(ΔΔCT) method. Methods 2001;25:402-8.
35. Langebrake C, Creutzig U, Dworzak M, Hrusak O, Mejstrikova E, Griesinger F, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM study group. MRD-AML-BFM Study Group. J Clin Oncol 2006;24:3686-92.
36. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S, et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123:243-52.
37. Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003;101:3398-406.
38. Gattenlohner S, Waller C, Ertl G, Bultmann BD, Muller-Hermelink HK, Marx A. NCAM(CD56) and RUNX1 (AML1) are up-regulated in human ischemic cardiomyopathy and a rat model of chronic cardiac ischemia. Am J Pathol 2003;163:1081-90.
39. Bekker MN, Arkesteijn JB, van den Akker NM, Hoffman S, Webb S, van Vugt JM, et al. Increased NCAM expression and vascular development in trisomy 16 mouse embryos: relationship with nuchal translucency. Pediatr Res 2005;58:1222-7.
40. Nagai R, Matsuura E, Hoshika Y, Nakata E, Nagura H, Watanabe A, et al. RUNX1 suppression induces megakaryocytic differentiation of UT-7/GM cells. Biochem Biophys Res Commun 2006;345:78-84.
41. Kivivuori SM, Rajantie J, Siimes MA. Peripheral blood cell counts in infants with Down's syndrome. Clin Genet 1996;49:15-9.
42. Hord JD, Gay JC, Whitlock JA. Thrombocytopenia in neonates with trisomy 21. Arch Pediatr Adolesc Med 1995;149:824-5.
43. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-49.
44. th Int.Symposium and Expert Workshops on Leukemia and Lymphoma Abstract Book; 2005.
45. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
46. Reinhardt D, Puhlmann U, Langebrake C. Molecular origin of childhood acute myeloid leukemia. Ann Hematol 2006;85:92-6.
47. Gilliland DG. Hematologic malignancies. Curr Opin Hematol 2001;8:189-91.